Biomet says selling on price is misplaced in orthopaedics
This article was originally published in Clinica
Executive Summary
Biomet's president and CEO Dane Miller agrees with analysts that a spin-off appears to be the most likely prospect for Bristol-Myer's Zimmer subsidiary. Speaking at the recent US Bancorp Piper Jaffray conference in New York, he also considered pricing trends in the orthopaedic industry.